News XTL Biopharmaceuticals Ltd. Nasdaq

Equities

XTLB

US98386D3070

Delayed Nasdaq Other stock markets 09:02:30 22/05/2024 pm IST			5-day change	1st Jan Change
2.67 ^USD	-4.64%		-2.55%	+164.33%

30/04	XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/04	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	01/05	CI
Top Premarket Gainers	29/04	MT
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	03/04	PU
XTL Biopharmaceuticals : Immediate Report of Meeting	22/03	PU
XTL Biopharmaceuticals : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 30, 2024 - Form 6-K	22/03	PU
XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding	20/03	CI
Top Midday Gainers	20/03	MT
XTL Biopharmaceuticals to Acquire The Social Proxy; Shares Soar	20/03	MT
XTL To Aquire The Social Proxy	20/03	AQ
XTL Biopharmaceuticals Ltd. entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd.	20/03	CI
XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	15/11	CI
XTL Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K	15/11	PU
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency	21/23/21	AQ
XTL Biopharmaceuticals : OPERATING AND FINANCIAL REVIEW AND PROSPECTS (Form 6-K)	25/21/25	PU
XTL Biopharmaceuticals Ltd. Elects Alexander Rabinovitch as Directors	03/17/03	CI
XTL Biopharmaceuticals Appoints Alex Rabinovich to its Board of Directors	27/17/27	CI
XTL Biopharmaceuticals Ltd. Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjögren’s Syndrome	05/17/05	CI
XTL Biopharmaceuticals Ltd. Announces Resignation David Kestenbaum as Chief Financial Officer	04/17/04	CI
XTL Biopharmaceuticals Ltd. Reports Audited Consolidated Earnings Results for the Full Year Ended December 31, 2016	30/17/30	CI
XTL Biopharmaceuticals Ltd. announced that it has received $2.8 million in funding	22/17/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News XTL Biopharmaceuticals Ltd. Nasdaq

Equities

XTLB

US98386D3070

Summary

Filters